Abbott laboratories (ABT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09
Cash Flow From (Used in) Operating Activities:
Net earnings

564

1,049

960

1,006

672

654

563

733

418

-828

603

283

419

798

-329

615

316

767

580

784

2,292

904

539

466

375

589

966

477

544

1,053

1,942

1,724

1,242

1,618

303

1,942

863

1,440

890

1,291

1,003

1,538

1,480

1,288

1,438

Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation

267

273

270

268

267

275

269

288

268

283

255

256

252

198

200

202

203

223

232

201

215

229

226

239

224

228

239

239

222

257

430

320

354

240

420

379

354

303

313

303

287

324

312

304

270

Amortization of intangible assets

561

483

484

483

486

488

544

562

584

560

501

392

522

121

140

145

144

143

151

151

156

166

129

161

174

198

197

197

199

330

329

370

389

407

417

432

391

406

363

371

275

222

228

233

193

Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-797

Share-based compensation

233

85

94

114

226

81

83

101

212

68

75

92

171

47

49

62

152

43

44

57

148

38

40

49

119

40

45

51

126

74

75

85

197

62

67

76

175

56

72

84

173

58

62

57

186

Amortization of inventory step-up

-

-

-

-

-

0

0

0

32

67

18

430

392

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impact of currency devaluation

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

4

0

477

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gains on sale of businesses

-

-

-

-

-

-

-

-

-

0

12

0

1,151

0

0

0

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

-1

2,821

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trade receivables

104

-82

22

165

170

-90

143

84

53

38

113

86

-30

61

-34

146

4

20

26

35

90

22

97

158

-82

135

-113

81

10

653

54

-611

-132

942

243

-216

-298

870

-230

45

-291

897

-82

-51

-375

Inventories

437

-137

190

254

286

64

114

165

171

-210

-166

-35

162

-54

3

54

95

44

3

82

128

94

62

51

90

-88

10

100

132

-48

85

208

170

177

2

-5

-44

-192

27

-23

49

-316

-194

81

198

Acquired in-process and collaborations research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

0

110

150

399

0

172

100

-

-

-

-

-

-

-

-

Other, net

369

-

-352

392

483

-

-981

191

182

-

-512

51

-101

-

-175

-85

1,261

-

-234

-71

-230

-

-426

-194

548

-

1,028

66

489

-

-881

947

69

-

-2,090

722

217

-

-705

-319

458

-

-669

139

770

Net Cash From Operating Activities

715

2,416

1,948

1,060

712

1,765

2,183

1,244

1,108

1,640

2,005

1,351

574

1,170

1,217

909

-93

828

1,195

941

2

1,238

1,201

900

336

1,625

522

717

460

1,502

3,519

2,066

2,224

1,401

3,054

2,503

2,011

2,316

2,548

2,348

1,522

1,832

3,030

1,713

698

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment

360

434

401

468

335

467

354

298

275

345

263

255

272

319

312

247

243

248

411

216

235

287

277

258

255

303

277

291

274

385

530

425

453

274

451

372

391

291

205

273

245

245

328

262

252

Acquisitions of businesses and technologies, net of cash acquired

-

-1

11

82

78

11

0

18

25

4,156

0

0

13,027

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

21

110

550

-

-

-

-

313

2,200

504

6,415

851

9

17

1,492

Proceeds from business dispositions

-

-

-

-

-

-

-

-

-

600

-29

-1

5,472

0

0

0

25

0

0

0

230

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of Mylan N.V. shares

-

-

-

-

-

-

-

-

-

727

53

239

1,685

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

367

-

-

-

1,834

9,751

-431

-1,222

3,899

-

-

-

-

-

-

-

-

-

-

-

-

Sales (purchases) of other investment securities, net

36

-

24

0

-2

-

-19

37

5

-

70

13

15

-4,691

182

1,246

-446

-6,738

570

1,843

213

-

-

-

-

-

-

-

-

-

-

-

-

-6,742

-1,932

1,108

1,917

1,019

-14

-1,085

-874

-2,911

1,177

1,856

-138

Deposit of restricted funds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,870

-

-

-

-

Other

-3

-4

-4

-4

-15

-17

-12

-6

-67

-5

-3

-24

-3

-8

-6

-30

2

-9

-15

-15

-13

-8

-35

0

-27

-

-

-

-

-1

10

-1

-11

-6

3

-4

-7

10

2

3

2

2

2

0

0

Net Cash (Used in) Investing Activities

-393

-489

-432

-498

-396

-496

-323

-299

-238

-3,152

-306

-6

-6,154

1,550

-554

-1,470

226

1,566

-1,197

242

-205

-10

-825

1,228

-595

840

-2,697

36

-2,108

-1,224

-131

688

-4,891

1,764

991

205

-2,301

-2,440

-2,392

303

-7,658

1,562

-1,518

-2,137

-1,605

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other

51

-

12

27

13

-48

-118

134

6

390

5

26

-1,455

-1,085

-397

298

-583

738

-501

-47

-1,471

74

397

-341

1,213

-1,438

374

902

2,248

-4

-1,908

1,297

1,399

-1,178

-1,961

778

396

1,215

-73

-2,120

775

936

-266

777

1,770

Proceeds from issuance of long-term debt and debt with maturities over 3 months

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,485

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,000

Repayments of long-term debt

1

2,918

2

21

500

4,154

999

1,301

5,979

6,142

1

2

2,505

1

1

3

7

21

3

23

10

-

-

-

-

-

-

-

-

11,017

0

0

54

1,003

2

1,506

500

1,672

0

0

1

0

0

500

1,983

Payment of contingent consideration

-

-

-

-

-

-

-

-

-

-

0

0

13

-

0

0

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of common shares

236

496

1

4

217

104

3

3

128

11

8

3

95

0

2

1

519

888

2

1

1,346

1

1

1

2,192

39

351

290

925

640

1

734

987

2

0

2

71

0

2

2

861

0

0

1

822

Proceeds from stock options exercised

89

7

47

117

127

27

74

33

137

75

89

57

129

42

76

43

87

51

50

57

156

139

64

56

170

215

38

73

69

279

524

359

687

651

47

93

175

56

68

15

188

186

29

13

279

Dividends paid

638

568

569

568

565

495

494

494

491

464

463

462

460

386

384

384

385

360

359

360

364

335

331

333

343

218

220

220

224

812

805

806

758

751

751

750

683

692

679

679

620

618

618

618

559

Net Cash (Used in) Financing Activities

-735

-2,185

-513

-449

-1,142

-4,776

2,471

-1,631

-6,455

-112

-386

-384

-4,399

13,504

-746

-179

-1,432

-497

-815

-374

-550

-700

-271

-619

-1,152

-1,869

-559

465

-4,733

2,505

-2,590

115

165

-1,684

-2,668

-1,386

-684

-93

-687

212

-520

503

-856

-329

1,684

Transfer of cash and cash equivalents to AbbVie Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,901

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contingent consideration payment related to a business acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

120

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-70

27

-49

2

4

-18

-27

-106

35

19

24

8

65

-104

5

-16

-368

-28

-99

13

-84

-78

-62

1

-4

-3

44

-19

-48

21

147

-163

34

282

-406

14

66

47

28

-110

-586

34

16

82

-14

Net Decrease in Cash and Cash Equivalents

-483

-231

954

115

-822

-3,525

4,304

-792

-5,550

-1,605

1,337

969

-9,914

16,120

-78

-756

-1,667

1,869

-916

822

-837

450

43

1,510

-1,415

593

-2,690

1,199

-6,429

2,804

944

2,706

-2,466

1,764

972

1,336

-908

-169

-503

2,754

-7,242

3,933

671

-670

762